Skip to main content
Clinical Trials/NCT05498493
NCT05498493CompletedNot Applicable

Assessing the Effectiveness of Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment: a Pilot Study

Icahn School of Medicine at Mount Sinai1 site in 1 country67 target enrollmentStarted: September 19, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
67
Locations
1
Primary Endpoint
Acceptability Scale

Study Overview

Brief Summary

This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally, the study will obtain preliminary data, using rsfMRI, regarding the potential underlying connectivity networks, mediating the effect of CR on cognitive improvements.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults ≥18 years of age
  • Have a confirmed SARS-CoV-2 infection (positive PCR or are serum antibody positive [against spike protein if unvaccinated or N-capsid peptide if vaccinated])
  • Speak English
  • Have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score >1.5 standard deviations below the normative mean) and in at least one other cognitive domain
  • Endorse comfort and familiarity with technology.

Exclusion Criteria

  • No method of contact
  • Major neurocognitive disorder, as defined by a score <17 on the Montreal Cognitive Assessment (MoCA)
  • History of pre-COVID-19 neurologic disease (e.g., stroke)
  • History of severe head injury (as defined by loss of consciousness >30 minutes)
  • Ongoing substance use disorder (Mini International Neuropsychiatric Interview Version 7.0.2 [MINI] or Alcohol Use Disorders Test-Consumption [AUDIT-C] >8)
  • Unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and
  • Contraindication for MRI (e.g., metallic/electronic implants).
  • Not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment

Arms & Interventions

Cognitive Rehabilitation

Experimental

Active Group participants will receive nine 1.5-h sessions of virtual (via Zoom platform) group-based training, three individual virtual 1-h training sessions, and approximately 20 h of home practice and CCT over 12 weeks.

Intervention: Cognitive Rehabilitation (Behavioral)

Brain Health Education Program

Active Comparator

The control group format will be twelve 1.5 or 1 h virtual sessions over 12 weeks, in addition to 20 h of home practice of a computerized control program (e.g., consisting of publicly available computer games such as sudoku and crossword puzzles).

Intervention: Brain Health Education Program (Behavioral)

Outcomes

Primary Outcomes

Acceptability Scale

Time Frame: end of study, at 12 months

Acceptability: using 7 Likert-rated items (scores will be coded as: Low: ≤3; Moderate: 3-3.9; Good: ≥4). Full range from 1-7, with higher score indicating higher acceptability.

Treatment Credibility and Expectancy Questionnaire.

Time Frame: end of study, at 12 months

Participants' beliefs about how likely they are to benefit from the intervention using the Treatment Credibility and Expectancy Questionnaire. Full scale from 0-10, with higher score indicating higher treatment expectancy.

Resting state functional connectivity (rsFC)

Time Frame: end of study, at 12 months

Neuroimaging Outcomes: Resting state functional connectivity (rsFC) within the central executive network (CEN).

Trail Making Test - Part B

Time Frame: end of study, at 12 months

Trail Making Test - Part B: a measure of aspects of executive functioning (e.g., set- shifting and cognitive flexibility), where participants connect the dots on a page scattered with numbers and letters in alternating sequence. Scored by time in seconds. Higher number of seconds implies deficiencies in cognitive functioning.

Enrollment yield

Time Frame: end of study, at 12 months

Practicality measured by enrollment yield which is #enrolled/approached.

Wisconsin Card Sorting Task (WCST)-64

Time Frame: end of study, at 12 months

Wisconsin Card Sorting Task (WCST)-64: Computer Version 2. The WCST-64 is a measure of executive functioning assessing novel problem solving and abstract thinking. The software scores the test and generates percentile scores (0-100). Scored by percentile. Higher percentile implies scoring better than others who have completed the task.

Dropout number

Time Frame: end of study, at 12 months

Practicality measured by number of dropout

Staff Practicality

Time Frame: end of study, at 12 months

Open-ended questions to staff regarding challenges conducting intervention (e.g., difficulty enrolling, reaching, engaging participants; scores will be coded as: Low: \<50%; Moderate: 50-70%; Good: \>70%).

Secondary Outcomes

  • The Symbol Digit Modalities Text (SDMT)(end of study, at 12 months)
  • The Hopkins Verbal Learning Test-Revised (HVLT-R)(end of study, at 12 months)
  • Wide Range Achievement Test, reading subtest, 4th edition (WRAT-4)(end of study, at 12 months)
  • Trail Making Test, Part A(end of study, at 12 months)
  • NACC battery's verbal phonemic and category fluency tests(end of study, at 12 months)
  • NACC battery's abbreviated Multilingual Naming Test (MINT)(end of study, at 12 months)
  • National Alzheimer's Coordinating Center (NACC) battery's Number Span(end of study, at 12 months)
  • Paced Auditory Serial Addition Task (PASAT)(end of study, at 12 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Juan Wisnivesky

Chief, Division of General Internal Medicine

Icahn School of Medicine at Mount Sinai

Study Sites (1)

Loading locations...

Similar Trials